Enzo Biochem, Inc. (ENZ) Downgraded by Zacks Investment Research
Enzo Biochem, Inc. (NYSE:ENZ) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company’s three wholly-owned subsidiaries–Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company’s research is the development of products based on two technology platforms — genetic modulation and immune modulation. “
Separately, BidaskClub raised Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th.
Shares of Enzo Biochem (NYSE:ENZ) traded down 0.62% on Tuesday, hitting $11.24. The stock had a trading volume of 200,111 shares. Enzo Biochem has a 1-year low of $4.88 and a 1-year high of $12.04. The firm has a 50 day moving average of $11.27 and a 200-day moving average of $9.01. The firm has a market capitalization of $521.61 million, a price-to-earnings ratio of 15.76 and a beta of 0.97.
TRADEMARK VIOLATION NOTICE: “Enzo Biochem, Inc. (ENZ) Downgraded by Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/15/enzo-biochem-inc-enz-downgraded-by-zacks-investment-research.html.
A number of hedge funds have recently modified their holdings of the company. Trexquant Investment LP bought a new stake in shares of Enzo Biochem during the first quarter valued at approximately $115,000. Legal & General Group Plc raised its stake in shares of Enzo Biochem by 10.6% in the second quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after buying an additional 1,022 shares during the period. Campbell & CO Investment Adviser LLC raised its stake in shares of Enzo Biochem by 24.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 14,325 shares of the medical research company’s stock valued at $120,000 after buying an additional 2,812 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Enzo Biochem during the second quarter valued at approximately $124,000. Finally, KCG Holdings Inc. bought a new stake in shares of Enzo Biochem during the first quarter valued at approximately $141,000. Institutional investors and hedge funds own 62.90% of the company’s stock.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.